Compare Stocks: IRON, PTGX, KYMR, and ARWR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$58.13 -4.3%	$77.91	$34.61 ▼ $95.49	$8.19B	1.29	2.28 million shs	2.25 million shs
IRON Disc Medicine	$56.60 -6.4%	$73.27	$40.00 ▼ $99.50	$2.17B	0.93	575,736 shs	594,318 shs
KYMR Kymera Therapeutics	$106.68 -4.8%	$115.14	$55.26 ▼ $130.05	$8.87B	1.98	746,911 shs	779,107 shs
PTGX Protagonist Therapeutics	$138.49 -4.4%	$145.89	$73.08 ▼ $160.81	$8.96B	1.53	721,601 shs	1.03 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-3.22%	-2.60%	-26.70%	-15.55%	+71.51%
IRON Disc Medicine	-2.55%	-4.50%	-13.67%	-19.37%	-13.48%
KYMR Kymera Therapeutics	-0.28%	+2.03%	-2.51%	0.00%	+95.91%
PTGX Protagonist Therapeutics	+0.80%	+3.02%	-2.23%	+10.37%	+66.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$58.13 -4.3%	$77.91	$34.61 ▼ $95.49	$8.19B	1.29	2.28 million shs	2.25 million shs
IRON Disc Medicine	$56.60 -6.4%	$73.27	$40.00 ▼ $99.50	$2.17B	0.93	575,736 shs	594,318 shs
KYMR Kymera Therapeutics	$106.68 -4.8%	$115.14	$55.26 ▼ $130.05	$8.87B	1.98	746,911 shs	779,107 shs
PTGX Protagonist Therapeutics	$138.49 -4.4%	$145.89	$73.08 ▼ $160.81	$8.96B	1.53	721,601 shs	1.03 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-3.22%	-2.60%	-26.70%	-15.55%	+71.51%
IRON Disc Medicine	-2.55%	-4.50%	-13.67%	-19.37%	-13.48%
KYMR Kymera Therapeutics	-0.28%	+2.03%	-2.51%	0.00%	+95.91%
PTGX Protagonist Therapeutics	+0.80%	+3.02%	-2.23%	+10.37%	+66.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.64	Moderate Buy	$98.31	69.12% Upside
IRON Disc Medicine	2.77	Moderate Buy	$110.18	94.67% Upside
KYMR Kymera Therapeutics	2.89	Moderate Buy	$134.68	26.25% Upside
PTGX Protagonist Therapeutics	2.94	Moderate Buy	$154.44	11.52% Upside

Current Analyst Ratings Breakdown

Latest IRON, PTGX, KYMR, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	PTGX Protagonist Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$184.00
10/12/2026	PTGX Protagonist Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$150.00 ➝ $190.00
10/8/2026	KYMR Kymera Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$140.00
10/8/2026	PTGX Protagonist Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/8/2026	KYMR Kymera Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$140.00
10/5/2026	KYMR Kymera Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$135.00 ➝ $150.00
9/24/2026	ARWR Arrowhead Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$74.00
9/23/2026	KYMR Kymera Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$140.00
9/22/2026	KYMR Kymera Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$132.00 ➝ $152.00
9/16/2026	IRON Disc Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$79.00 ➝ $86.00
9/14/2026	KYMR Kymera Therapeutics	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$123.00 ➝ $144.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$669.50M	12.23	$0.11 per share	525.54	$3.64 per share	15.97
IRON Disc Medicine	N/A	N/A	N/A	N/A	$19.52 per share	N/A
KYMR Kymera Therapeutics	$39.21M	226.23	N/A	N/A	$19.42 per share	5.49
PTGX Protagonist Therapeutics	$46.02M	194.73	N/A	N/A	$9.83 per share	14.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	11/24/2026 (Estimated)
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	11/5/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	134.46	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)

Latest IRON, PTGX, KYMR, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	IRON Disc Medicine	-$1.63	N/A	N/A	N/A	$1.88 million	N/A
11/5/2026	Q3 2026	PTGX Protagonist Therapeutics	$2.38	N/A	N/A	N/A	$241.46 million	N/A
11/3/2026	Q3 2026	KYMR Kymera Therapeutics	-$1.27	N/A	N/A	N/A	$3.10 million	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
IRON Disc Medicine	0.09	24.14	24.14
KYMR Kymera Therapeutics	N/A	10.34	10.34
PTGX Protagonist Therapeutics	N/A	21.71	21.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
IRON Disc Medicine	83.70%
KYMR Kymera Therapeutics	N/A
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
IRON Disc Medicine	3.76%
KYMR Kymera Therapeutics	15.98%
PTGX Protagonist Therapeutics	5.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	711	140.86 million	135.79 million	Optionable
IRON Disc Medicine	165	38.39 million	36.95 million	Not Optionable
KYMR Kymera Therapeutics	273	83.15 million	69.86 million	Optionable
PTGX Protagonist Therapeutics	141	64.71 million	61.35 million	Optionable

IRON, PTGX, KYMR, and ARWR Headlines

Recent News About These Companies

Head to Head Contrast: Protagonist Therapeutics (NASDAQ:PTGX) & AbCellera Biologics (NASDAQ:ABCL)

October 13 at 5:15 AM | americanbankingnews.com

UBS initiates coverage of Protagonist Therapeutics with buy rating

October 12 at 2:43 PM | msn.com

Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology

October 12 at 2:43 PM | msn.com

UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target

October 12 at 9:43 AM | marketscreener.comM

Protagonist Therapeutics' (PTGX) Outperform Rating Reaffirmed at Leerink Partners

October 12 at 9:06 AM | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Stock Keeps "Outperform" Rating at Leerink Partners

October 12 at 9:05 AM | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) & Halozyme Therapeutics (NASDAQ:HALO) Financial Survey

October 11 at 7:58 AM | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to Buy at Wall Street Zen

October 10 at 1:25 AM | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to "Buy" at Wall Street Zen

October 10 at 1:23 AM | marketbeat.com

Protagonist Therapeutics stock fell 1.38 percent on October 6

October 6, 2026 | ad-hoc-news.deA

Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 58,629 Shares of Stock

October 3, 2026 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Stock: Insider Asif Ali Sells 58,629 Shares

October 3, 2026 | insidertrades.com

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 58,629 Shares of Company Stock

October 2, 2026 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Rated "Moderate Buy" by Wall Street Brokerages

October 2, 2026 | americanbankingnews.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts

October 2, 2026 | marketbeat.com

Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - What's Next?

September 25, 2026 | marketbeat.com

1,324,498 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Bank of America Corp DE

September 18, 2026 | marketbeat.com

California State Teachers Retirement System Acquires 284 Shares of Protagonist Therapeutics, Inc. $PTGX

September 14, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX

September 13, 2026 | marketbeat.com

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 7,278 Shares

September 11, 2026 | insidertrades.com

Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRON, PTGX, KYMR, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$58.13 -2.60 (-4.28%)

Closing price 04:00 PM Eastern

Extended Trading

$58.54 +0.40 (+0.70%)

As of 05:12 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Disc Medicine NASDAQ:IRON

$56.60 -3.88 (-6.42%)

Closing price 04:00 PM Eastern

Extended Trading

$56.54 -0.05 (-0.10%)

As of 04:10 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics NASDAQ:KYMR

$106.68 -5.40 (-4.82%)

Closing price 04:00 PM Eastern

Extended Trading

$106.77 +0.09 (+0.08%)

As of 04:54 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Protagonist Therapeutics NASDAQ:PTGX

$138.49 -6.39 (-4.41%)

Closing price 04:00 PM Eastern

Extended Trading

$138.55 +0.06 (+0.04%)

As of 04:48 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRON, PTGX, KYMR, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRON, PTGX, KYMR, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRON, PTGX, KYMR, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRON, PTGX, KYMR, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Disc Medicine NASDAQ:IRON

Kymera Therapeutics NASDAQ:KYMR

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRON, PTGX, KYMR, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRON, PTGX, KYMR, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRON, PTGX, KYMR, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRON, PTGX, KYMR, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Disc Medicine NASDAQ:IRON

Kymera Therapeutics NASDAQ:KYMR

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools